MAPT and Alzheimer disease: The absence of significant changes related to AD severity that we observed for Aβ42 and P-T181-tau seem to indicate that major changes in these blood markers occur early in AD pathology, as supported by the findings that alterations in NDEV and CSF levels of both parameters are similar in the preclinical and dementia stages of AD [10, 11, 18, 58].